A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).

Hallucinations and delusions are common in dementia and may be comorbid or part of the disease process (ie, dementia related psychosis [DRP]). DRP occurs in 30% of people with any type of dementia, 40% of those with Alzheimer disease and 70% of dementia with Lewy bodies.

Not all physicians who treat Alzheimer's disease will prescribe the new Alzheimer's drug aducanumab (Aduhelm) -- major hospital systems like the Cleveland Clinic and Mount Sinai in New York City, for example, won't administer the controversial treatment -- but those who will offer the drug need more information about how to use it, a panel of neuroscientists said.

Appropriate use recommendations for the newly approved Alzheimer disease treatment, aducanumab (Aduhelm; Biogen, Cambridge, MA) have been published in The Journal of Prevention of Alzheimer’s Disease (JPAD).

Clinical experts have published the first set of clinical guidelines for appropriately using the newly approved Alzheimer’s drug aducanumab — brand name Aduhelm.

Treatment of early Alzheimer’s patients with Biogen’s new drug Aduhelm should closely resemble how the drug was studied in its pivotal clinical trials, according to new recommendations from a panel of neuroscience experts led by UNLV’s Jeffrey Cummings.

A group of six leading Alzheimer’s experts have convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.